The Efficacy of Dexamethasone in Combination With N-acetylcysteine in Preventing Neurocognitive Sequelae Due to Carbon Monoxide Poisoning

Last updated: March 23, 2025
Sponsor: China Medical University Hospital
Overall Status: Active - Recruiting

Phase

4

Condition

N/A

Treatment

Dexamethasone and N-acetylcysteine (NAC)

Placebo

Clinical Study ID

NCT06811675
CMUH113-REC1-201
  • Ages > 18
  • All Genders

Study Summary

Background and Aim: Carbon monoxide (CO) poisoning is a significant public health issue that can cause delayed neuropsychological sequelae (DNS). DNS mechanisms involve oxidative stress, inflammation, and immune injury. Although hyperbaric oxygen therapy is widely used, its efficacy in preventing DNS remains inconclusive. Preclinical and retrospective studies suggest that Dexamethasone (anti-inflammatory and immunosuppressive) and N-acetylcysteine (antioxidant) may reduce DNS risk. This study hypothesizes that their combination can effectively prevent DNS.

Methods: This prospective pre-post intervention study will enroll CO poisoning patients into treatment (Dexamethasone + N-acetylcysteine) and control groups. The primary outcome is the incidence of DNS within six weeks post-treatment.

Objective: To determine whether combining Dexamethasone and N-acetylcysteine reduces the incidence of DNS following CO poisoning.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • History and clinical symptoms consistent with CO poisoning (initial bloodcarboxyhemoglobin (COHb) levels >5%, or >10% for smokers).

Exclusion

Exclusion Criteria:

  • Concurrent use of other potentially lethal toxins. Severe trauma or burns that couldbe fatal. No spontaneous heartbeat or blood pressure before arrival. Poisoning timeexceeding 24 hours before hospital arrival. Minors (under 18 years of age). Pregnantwomen. Patients or their families refuse to sign the consent form. Contraindicationsfor the use of Dexamethasone or N-acetylcysteine (such as severe allergies) or whenthe physician assesses the risks outweigh the benefits.

Study Design

Total Participants: 128
Treatment Group(s): 2
Primary Treatment: Dexamethasone and N-acetylcysteine (NAC)
Phase: 4
Study Start date:
March 23, 2025
Estimated Completion Date:
September 30, 2027

Connect with a study center

  • China Medical University Hospital

    Taichung, 404022
    Taiwan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.